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Dietmar MansteinProf. Dietmar Manstein, Director of the Institutes for Biophysical
Chemistry and Structural Analysis at the Medical School of Han-
nover, is a member of the FEBS Letters Editorial Board since 2008.
While being reserved and of gentle ways, Prof. Manstein is an
assiduous scientist and an enthusiastic ‘‘molecular inventor’’, whose
creative streak often crosses the boarder between basic research and
biomedical applications.
1. In 25 years of career as a researcher, myosin appears to be
the everlasting constant in your studies
Yes. Myosin is the classic example of a molecular motor, a pro-
tein that uses chemical energy to move along ﬁlament tracks, and
it is a complex molecule that offers a number of biochemical, phys-
ical, structural and physiological riddles to solve. My studies on
myosin have taken me to areas of molecular biology I hardly knew
in the ﬁrst place. When I started working with myosin in 1986, re-
combinant biology was moving its ﬁrst steps. As myosin is post-
translationally modiﬁed, we were not able to express recombinant
myosin in bacteria. Therefore, I set up a tool kit for the molecular-
genetic manipulation of Dictyostelium discoideum [1], which I used
for the expression of recombinant motors [2]. Dictyostelium proved
to be a genetically amenable system for our needs, as it is eukary-
otic, it has a rapid cell cycle, and it requires myosin for cell division.
This system allowed us to mutate the protein for a series of struc-
tural and functional studies, which revealed how actin-based mo-
tors move along thin ﬁlaments.
2. What seems to distinguish your research strategy is the use
of molecular engineering, or the creation of new artiﬁcial
molecules, as a proof of concept of your theories
In principle, I believe that if you have a valid idea, you should be
able to generate a system that can demonstrate that your idea is
correct.
In 1993, the crystal structure of the globular head of myosin
was published in Science by our competitors [3]. It showed the
ATP binding site and the actin binding site, separated by a cleft,
which allowed the transformation of chemical energy into
mechanical movement. However, the movement within the cleft
was within the range of 2 Å, whereas the displacement of myosin
along the actin ﬁlament was greatly ampliﬁed. How did the ampli-0014-5793/$36.00  2011 Federation of European Biochemical Societies. Published by E
doi:10.1016/j.febslet.2011.07.001ﬁcation take place? We suspected that a long lever arm-like struc-
ture emerging from the globular domain plays a role. To
demonstrate it, we engineered myosin by substituting this region
with stiff, elongated modules made from a-actinin repeats [4].
We were able to show that the extent of ampliﬁcation is dependent
on the length of this region, and that the force and other properties
can also be modiﬁed by genetic engineering.
Myosins move in a speciﬁc direction along the polarized actin
ﬁlament. Most myosins move forwards, towards the barbed (+)
end, but one class of myosin is known to move backwards, towards
the pointed () end. My next goal was to understand what deter-
mines the direction of movement. A study published in Nature sug-
gested that the direction depended on the angle by which the core
domain of myosin binds to the actin ﬁlament [5]. Somehow, I was
not convinced, as the interface of actin and myosin had coevolved
for millions of years, and this explanation would not justify the
existence of a single class of myosins that moves backwards but,
based on sequence comparison, has a generic motor domain. Evo-
lution mostly takes place via duplications, rearrangements, and
insertions of pre-existing domains. My hypothesis was that the le-
ver arm had at some point ﬂipped over. Once again, as a proof of
concept, we created an engineered myosin with an artiﬁcial lever
arm that was rotated by 180, and sure enough it moved back-
wards [6]. Work by the laboratories of Anne Houdusse and Lee
Sweeney showed later that a reorientation of the lever arm
brought about by an insertion at the base of the lever arm is indeed
responsible for the backwards movement of myosin-6 [7].
3. Are there any potential heterologous applications for
molecular motors?
We recently published the application of molecular motors as
nanovalves to quickly detect disease markers that are very dilute
on a small chip [8]. The receptor of a disease marker is crosslinked
to myosin. Once the marker loads onto the myosin, the motor runs
it into a funnel that concentrates it, making it easily identiﬁable by
antibodies.
However, most importantly myosin is an optimal working mod-
el for studying allosteric coupling in drug discovery. Motor pro-
teins have more measurable parameters than most enzymes,
including force intensity, extent of movement and spectroscopic
signals besides the biochemical activity, and such features allowlsevier B.V. All rights reserved.
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molecule with the protein. Many modulators of protein activity do
not sit directly in the active site, but bind to side pockets that
somehow interfere with the activity of the protein. On one hand,
we are using myosin to identify pharmacological leads that recog-
nize speciﬁc types of pockets, where their interaction with protein
surface residues inﬂuences the active site over larger distances.
These studies should be of use on a broad scale of different en-
zymes. On the other hand, we are trying to identify inhibitors, acti-
vators, uncouplers and pharmacological chaperones, which are
speciﬁc for certain myosin subtypes [9–11]. Myosins have a funda-
mental role in cell motility as well as in proliferation and certain
types of signalling. Blocking their function is considered a possible
therapeutic approach for treatment of cancer and metastasis. In
addition, we use myosin inhibitors to target apicomplexa, such as
Plasmodium falciparum and Toxoplasma, which have a distinct spe-
cies-speciﬁc myosin. With the help of the universities of Hannover
and Dresden, we have created a company called Kinaris to backup
the initial work carried out in our academic labs with high-
throughput screenings, and to cover the costs of the intellectual
property associated to this project.4. Which part of your work do you enjoy the most?
There are different stages that I like. First of all it is getting an
idea. I like to tell my students that ideas are cheap in science,
but they can be a distraction. One needs to pick a problem, stay fo-
cused, and persevere until the idea has been brought to fruition. At
the beginning, when things are not working out you need stamina
and determination, you just have to keep at it. However, when
after a year or two I ﬁnally see something happening, a ﬁrst
encouraging result, then I cannot sleep. I get up at four o’clock in
the morning to go to the lab to follow the experiment. It is totally
exhausting, and after two or three months I simply collapse. How-
ever, most of the times I get my result before that happens. My
hyperactivity culminates at the moment of veriﬁcation. I remem-ber sitting in front of the microscope with my two postdocs when
we observed for the ﬁrst time that our backwards-moving motor
worked: an intoxicating moment of joy that instantly brings your
energy level back to 100%.
Another example is when we found a number of small mole-
cules that modulate myosin motor function. We had a hard time
ﬁguring out why these different molecules could all bind the same
pocket and what they had in common. It took months of painstak-
ing dissection of the positional movements of hundreds of struc-
tures at the Å level. It is like being in a pitch-dark forest. Then,
all of a sudden, something lights up, ﬁreﬂies show you the way
out of the darkness. It all makes sense, and you think: ‘‘Why ha-
ven’t I been seeing it all along?’’
I also like when I look at the literature and suddenly ﬁnd the
missing piece of the puzzle. Once your project gets going, after
months of apparently futile toiling, results seem to start falling into
your lap, things seem to happen all by themselves.
In science you constantly change and evolve, moving from
method to method, from one intellectual challenge to another.
You just need to be open-minded and follow the path the protein
takes you along.
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